Iclusig
Ended Awarded Last action
- Contract number
- 36C26025F0003
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI ENNFDLWFC6L1
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $28,395
Award facts
- Contract value 100% obligated
- $28,394.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Earth City, MO 63045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$27,432 | |
| Funding Only Action | -$41,870 | |
| Original award | $97,697 |
About this award
Takeda Pharmaceuticals America, Inc. received a delivery order award valued at $28,394.78 for the supply of ICLUSIG (ponatinib), an oncology medication, with an ultimate completion date of September 30, 2025. The contract is a firm fixed-price delivery order placed against Takeda's GSA Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and was awarded without a small business set-aside designation. The Veterans Integrated Service Network 20, a civilian component of the Department of Veterans Affairs, is the funding federal agency, with the place of performance located in Earth City, Missouri.
This delivery order represents a continuation of Takeda's established role as a critical pharmaceutical supplier to the VA, supported by two significant indefinite delivery vehicles: a Federal Supply Schedule contract valued at nearly $2.9 billion through September 2030 and a single-award Blanket Purchase Agreement valued at $123.5 million specifically for ICLUSIG supply to VA medical facilities through the National Acquisition Center. The streamlined procurement mechanisms enable VA medical facilities to efficiently order specialized oncology treatments, demonstrating the VA's reliance on Takeda as a key provider of this critical pharmaceutical treatment for veteran healthcare.
Quick answers
Who was awarded contract 36C26025F0003?
36C26025F0003 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C26025F0003 worth?
The government has obligated $28,395 on 36C26025F0003.
Is contract 36C26025F0003 an order under another contract?
Yes. 36C26025F0003 is a delivery order under 36F79718D0586, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0003 competed?
The extent of competition for 36C26025F0003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award